Our
Story

Our team started together at the University of Antwerp in 2019. We combined our diverse backgrounds across research, engineering, and business to tackle urgent challenges in cancer research. In 2023, we officially incorporated Orbits Oncology in the USA.

Our mission is to bring patient insights early cancer drug discovery and development research, by unlocking the predictive potential of patient-derived organoids. Our technology will help biopharma bring the right drugs to market and match them with the right patients.